Efficacy and safety of xanthoxine combined with low-dose calcitriol in dialysis patients with secondary hyperparathyroidism
Objective To investigate the efficacy and safety of xinaxacet combined with lowdose calcitriol in patients with secondary hyperparathyroidism.Methods Eighty-four patients with secondary hyperparathyroidism who had been diagnosed as end-stage renal disease and who had been dialyzed from January 2012...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Nephrology
2017-01-01
|
| Series: | Linchuang shenzangbing zazhi |
| Subjects: | |
| Online Access: | http://www.lcszb.com/thesisDetails?columnId=57916789&Fpath=home&index=0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850142968851202048 |
|---|---|
| author | LUO Zhen SHI Tian-li ZHOU Jun PAN Miao-xia |
| author_facet | LUO Zhen SHI Tian-li ZHOU Jun PAN Miao-xia |
| author_sort | LUO Zhen |
| collection | DOAJ |
| description | Objective To investigate the efficacy and safety of xinaxacet combined with lowdose calcitriol in patients with secondary hyperparathyroidism.Methods Eighty-four patients with secondary hyperparathyroidism who had been diagnosed as end-stage renal disease and who had been dialyzed from January 2012 to September 2015,including 41 males and 43 females with age ranging from61 to 89 years old,were randomly divided into two groups(n=42 each group).All patients underwent basic treatment of end-stage renal disease,including diet control,pressure reduction,and erythropoietin treatment.According to the results of laboratory tests to determine the amount of treatment or reduction or maintenance of the existing dose,every 2 to 4 weeks to adjust the dose.The control group was treated with oral cinnarashcitate tablets at an initial dose of 25 mg/d and a maximum dose of 75 mg/d.Treatment group in the control group based on oral ossification triol capsules,the initial dose of 0.25μg/d,Every 2 to 4 weeks to adjust the dose,if the tolerance is adjusted to the maximum dose of 0.5μg/d.Both groups were treated continuously for 3 months.The levels of serum calcium,serum phosphorus and total immunoreactive parathyroid hormone(iPTH)were measured before and 6 months after treatment,and the results were statistically analyzed.Results After treatment for 6 months,the levels of iPTH and serum phosphorus in both groups were significantly decreased(P<0.05),and the levels of serum calcium in the treatment group had no significant change(P>0.05).The level of serum calcium in the control group was decreased as compared with that before treatment(P<0.05).As compared with the control group,the iPTH in the treatment group decreased more significantly(P<0.05).Conclusions The combination of cenolafine and low-dose calcitriol can reduce parathyroid hormone and the level of blood phosphorus in patients with terminal hyperthyroidism,and can obtain safe and effective therapeutic effect. |
| format | Article |
| id | doaj-art-a5ec4ee5fce44331b0487e95036f90ca |
| institution | OA Journals |
| issn | 1671-2390 |
| language | zho |
| publishDate | 2017-01-01 |
| publisher | Editorial Department of Journal of Clinical Nephrology |
| record_format | Article |
| series | Linchuang shenzangbing zazhi |
| spelling | doaj-art-a5ec4ee5fce44331b0487e95036f90ca2025-08-20T02:28:51ZzhoEditorial Department of Journal of Clinical NephrologyLinchuang shenzangbing zazhi1671-23902017-01-0143143457916789Efficacy and safety of xanthoxine combined with low-dose calcitriol in dialysis patients with secondary hyperparathyroidismLUO ZhenSHI Tian-liZHOU JunPAN Miao-xiaObjective To investigate the efficacy and safety of xinaxacet combined with lowdose calcitriol in patients with secondary hyperparathyroidism.Methods Eighty-four patients with secondary hyperparathyroidism who had been diagnosed as end-stage renal disease and who had been dialyzed from January 2012 to September 2015,including 41 males and 43 females with age ranging from61 to 89 years old,were randomly divided into two groups(n=42 each group).All patients underwent basic treatment of end-stage renal disease,including diet control,pressure reduction,and erythropoietin treatment.According to the results of laboratory tests to determine the amount of treatment or reduction or maintenance of the existing dose,every 2 to 4 weeks to adjust the dose.The control group was treated with oral cinnarashcitate tablets at an initial dose of 25 mg/d and a maximum dose of 75 mg/d.Treatment group in the control group based on oral ossification triol capsules,the initial dose of 0.25μg/d,Every 2 to 4 weeks to adjust the dose,if the tolerance is adjusted to the maximum dose of 0.5μg/d.Both groups were treated continuously for 3 months.The levels of serum calcium,serum phosphorus and total immunoreactive parathyroid hormone(iPTH)were measured before and 6 months after treatment,and the results were statistically analyzed.Results After treatment for 6 months,the levels of iPTH and serum phosphorus in both groups were significantly decreased(P<0.05),and the levels of serum calcium in the treatment group had no significant change(P>0.05).The level of serum calcium in the control group was decreased as compared with that before treatment(P<0.05).As compared with the control group,the iPTH in the treatment group decreased more significantly(P<0.05).Conclusions The combination of cenolafine and low-dose calcitriol can reduce parathyroid hormone and the level of blood phosphorus in patients with terminal hyperthyroidism,and can obtain safe and effective therapeutic effect.http://www.lcszb.com/thesisDetails?columnId=57916789&Fpath=home&index=0Secondary hyperparathyroidismXinacacusCalcitriolEnd stage renal disease |
| spellingShingle | LUO Zhen SHI Tian-li ZHOU Jun PAN Miao-xia Efficacy and safety of xanthoxine combined with low-dose calcitriol in dialysis patients with secondary hyperparathyroidism Linchuang shenzangbing zazhi Secondary hyperparathyroidism Xinacacus Calcitriol End stage renal disease |
| title | Efficacy and safety of xanthoxine combined with low-dose calcitriol in dialysis patients with secondary hyperparathyroidism |
| title_full | Efficacy and safety of xanthoxine combined with low-dose calcitriol in dialysis patients with secondary hyperparathyroidism |
| title_fullStr | Efficacy and safety of xanthoxine combined with low-dose calcitriol in dialysis patients with secondary hyperparathyroidism |
| title_full_unstemmed | Efficacy and safety of xanthoxine combined with low-dose calcitriol in dialysis patients with secondary hyperparathyroidism |
| title_short | Efficacy and safety of xanthoxine combined with low-dose calcitriol in dialysis patients with secondary hyperparathyroidism |
| title_sort | efficacy and safety of xanthoxine combined with low dose calcitriol in dialysis patients with secondary hyperparathyroidism |
| topic | Secondary hyperparathyroidism Xinacacus Calcitriol End stage renal disease |
| url | http://www.lcszb.com/thesisDetails?columnId=57916789&Fpath=home&index=0 |
| work_keys_str_mv | AT luozhen efficacyandsafetyofxanthoxinecombinedwithlowdosecalcitriolindialysispatientswithsecondaryhyperparathyroidism AT shitianli efficacyandsafetyofxanthoxinecombinedwithlowdosecalcitriolindialysispatientswithsecondaryhyperparathyroidism AT zhoujun efficacyandsafetyofxanthoxinecombinedwithlowdosecalcitriolindialysispatientswithsecondaryhyperparathyroidism AT panmiaoxia efficacyandsafetyofxanthoxinecombinedwithlowdosecalcitriolindialysispatientswithsecondaryhyperparathyroidism |